US20080293637A1 - Cross-linked collagen and uses thereof - Google Patents
Cross-linked collagen and uses thereof Download PDFInfo
- Publication number
- US20080293637A1 US20080293637A1 US12/125,337 US12533708A US2008293637A1 US 20080293637 A1 US20080293637 A1 US 20080293637A1 US 12533708 A US12533708 A US 12533708A US 2008293637 A1 US2008293637 A1 US 2008293637A1
- Authority
- US
- United States
- Prior art keywords
- cross
- collagen
- linked
- linked collagen
- fibrillar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates in general to body treating compositions and methods. More specifically, the invention provides a cross-linked collagen implant of improved volume stability (“persistence”) for augmenting soft tissue in mammals.
- Collagen has been used as a pharmaceutical carrier, as a surgical prosthesis (sutures and wound dressings), and as an implant material.
- the collagen is cross-linked with chemical agents, radiation, or other means to improve its mechanical properties, decrease its immunogenicity, and/or increase its resistance to resorption.
- U.S. Pat. No. 4,424,208 describes a collagen composition including cross-linked collagen and reconstituted collagen fibers having enhanced persistence. While these materials are remarkably effective, they shrink in volume after implantation due primarily to absorption of their fluid component by the body, although the shrinkage (syneresis) is less than non-cross-linked collagen. Since a constant volume or persistence is desirable, an additional injection or injections of supplemental implant material is required. It would thus be advantageous to provide collagen compositions having enhanced persistence after being introduced in vivo to a soft tissue treatment site.
- the present invention relates to collagen cross-linked in a micro to non-fibrillar form and at a high concentration for augmenting soft tissue in mammals.
- the cross-linked collagen of the present invention has improved volume stability or persistence compared with collagen cross-linked at a neutral pH.
- the invention features a method for preparing cross-linked collagen.
- the method involves the steps of obtaining micro to non-fibrillar collagen, treating the micro to non-fibrillar collagen with a cross-linking agent, and isolating cross-linked collagen.
- the micro to non-fibrillar collagen may be obtained by incubating fibrillar collagen in a suspension or solution of pH 2-5 or pH 9-12. In a preferred embodiment, the pH of the suspension or solution is between 4.2 and 5.0.
- the concentration of the micro to non-fibrillar collagen at the time of cross-linking is in the range of 3-150 mg/mL, and preferably, 38-52 mg/mL.
- the treating step includes treating the micro to non-fibrillar collagen with the cross-linking agent at pH 2-5 or pH 9-12, followed by treating the micro to non-fibrillar collagen with the cross-linking agent at pH 6-8 to encourage completion of the cross-linking.
- the method of the invention optionally may further include a step of admixing a local anesthetic agent (e.g., lidocaine) with the cross-linked collagen.
- a local anesthetic agent e.g., lidocaine
- cross-linked collagen comprising micro to non-fibrillar collagen and a cross-linking agent.
- the micro to non-fibrillar collagen is cross-linked by the cross-linking agent.
- Such cross-linked collagen may be prepared according to the method described above.
- the cross-linked collagen may derive from type I, II, III, IV, or V collagen, or a combination thereof. It may also derive from telo-containing collagen, atelo-collagen, or derivatized collagen, or a combination thereof.
- the cross-linking agent is capable of forming covalent bonds between amino acid residues in the micro to non-fibrillar collagen.
- suitable cross-linking agents include, but are not limited to, carbodiimides, polyaldehydes, polysulfones, activated PEGs, epoxides, imidazoles, and diisocyanates.
- the cross-linking agent is glutaraldehyde.
- the number of free hydroxy lysine and lysine residues per 1000 amino acid residues is in the range of 22-32, and more typically, in the range of 24-29.
- the cross-linked collagen of this invention is in a gel but not fibrous state. It locks water in the gel and does not disperse like a fibrous collagen suspension.
- the cross-linked collagen in a gel state maintains its shape in vivo better than cross-linked collagen in a fibrous state.
- the fibers of the cross-linked collagen are smaller than those of fibrous collagen cross-linked at a neutral pH.
- the invention further provides a composition containing the cross-linked collagen of the invention and a local anesthetic agent such as lidocaine.
- the local anesthetic agent is admixed with the cross-linked collagen.
- the invention provides a packaged product containing a syringe fitted with a needle, wherein the syringe is loaded with the cross-linked collagen of the invention.
- the invention features a method for filling voids and defects and increasing tissue volume in a mammal.
- the method involves administering to a mammal the cross-linked collagen of the invention.
- the cross-linked collagen is administered by intradermal or subcutaneous injection.
- micro to non-fibrillar collagen refers to collagen with a diameter of 5-70 nm; “fibrillar collagen” refers to collagen with a diameter of >70 nm; “fibrous collagen” refers to fibrillar collagen and larger fibers.
- Telo-containing collagen refers to collagen with intact telo peptide; “atelo-collagen” refers to collagen wherein the telo portions are removed partially or totally; “derivatized collagen” refers to chemically modified collagen. Examples of derivatized collagen include, but are not limited to, deamidated, methylated, succinylated, and phosphorylated collagen.
- Cross-linked collagen in a “gel state” contains micro to non-fibrillar collagen with a fiber diameter range of 5-70 nm; cross-linked collagen in a “fibrous state” contains fibrillar collagen with a fiber diameter of greater than 70 nm.
- free hydroxyl-lysine and lysine in collagen refers to unmodified hydroxyl-lysine and lysine; “neutral pH” refers to pH 6-8.
- the present invention provides a cross-linked collagen filler for augmenting and filling soft tissue defects and voids with a material that plumps and bulks the soft tissue.
- the cross-linking collagen of the invention is particularly useful for deep dermal correction and sculpting.
- the superior shape retention makes it ideal for areas that are hard to correct and where a biocompatible bolus can provide mechanical strength to the body.
- FIG. 1 is a flow chart illustrating representative conventional and inventive processes for preparation of cross-linked collagen.
- FIG. 2 shows the persistence of the inventive cross-linked collagen relative to the conventional cross-linked collagen.
- the present invention is based, at least in part, on the unexpected discovery that collagen cross-linked in a micro to non-fibrillar state and preferably at a high concentration has improved persistence compared to collagen cross-linked at a neutral pH.
- fibrillar collagen is fairly porous and allows the transport of cells and large molecules.
- cross-linking smaller fiber (microfibrillar) collagen more rigidity within the network was created to further increase the diffusion hindrance (Rosenblatt and Shenoy, 1993, Chain Rigidity and Diffusional Release in Biopolymer Gels, Proceed Intern Symp Control Rel Bioact Mater 20 , Controlled Release Society, Inc.).
- Cross-linked micro-fibrillar collagen has a tighter network or mesh, which creates a collagen matrix more resistant or persistent to biological degradation.
- type I collagen matrices were modified to reduce the penetration of cells and proteins into the matrices.
- the present invention is particularly directed to the filling of voids and defects and increasing tissue volume in mammals with injectable cross-linked Type I/III collagen implants. Accordingly, the invention provides a method for preparing cross-linked collagen by cross-linking collagen in a micro to non-fibrillar state and preferably at a high concentration.
- the cross-linked collagen of the present invention primarily derives from mammalian source materials, such as bovine or porcine corium, although human placenta material, collagen produced from human fibroblast cell culture, or recombinantly produced collagen expressed from a cell line may also be used.
- mammalian source materials such as bovine or porcine corium
- human placenta material collagen produced from human fibroblast cell culture, or recombinantly produced collagen expressed from a cell line may also be used.
- the donor need not be genetically similar to the host into which the material is ultimately implanted.
- purified, type I, pepsin digested human collagen from Allergan Medical Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) is reconstituted from a solution by neutralizing the solution at reduced temperatures and ionic strengths hypotonic relative to physiological conditions.
- the pH of the solution is raised to a level at which the collagen in solution reaggregates into fibrils.
- the reconstituted fibrous collagen is cross-linked with a cross-linking agent at a neutral pH.
- the cross-linked collagen is then harvested by centrifugation, formulated/homogenized, smoothed, and screened.
- the process of the present invention involves concentrating the collagen suspension by centrifugation.
- the pellet is homogenized, and the pH is adjusted to a non-neutral level prior to cross-linking.
- the collagen concentration at the time of cross-linking is usually in the range of 3-150 mg/mL, more typically 30-60 mg/mL, 35-55 mg/mL, or 38-52 mg/mL.
- the pH is adjusted to a non-neutral level appropriate for the cross-linking agent to be used.
- the pH may be adjusted to about 4.5 for cross-linking by glutaraldehyde or to about 10 for cross-linking by divinylsulfone.
- a dilute solution of HCl or the like is typically added to adjust the pH to a desired acidic level, while NaOH or the like is used for adjusting the pH to a desired alkaline level.
- the cross-linking begins at pH 2-5 or pH 9-12, more preferably at pH 2-3, 2-4, 3-4, 3-5, or 4-5, or pH 9-10, 9-11, 10-11, 10-12, or 11-12.
- the collagen fiber is unraveled to a micro to non-fibrillar state. More lysine groups are exposed and available for cross-linking.
- a high collagen concentration increases the reaction rate.
- the collagen is stabilized while being cross-linked into small fiber structures.
- the pH is further adjusted to a neutral pH, e.g., pH 6-8, using 0.5 M phosphate, pH 11.2, or the like, to encourage complete cross-linking.
- the pH can then be adjusted back to neutral without causing the cross-linked collagen gel to collapse or to spontaneously form fibers.
- a cross-linking agent is polyfunctional, and more usually bifunctional.
- the cross-linking conditions of the present invention are such as to produce covalently cross-linked collagen that has improved persistence relative to an implant of a comparable formulation prepared according to the conventional process.
- the cross-linking reaction is optionally quenched by adding a quenching agent.
- the quenching agent forms a water soluble adduct with the cross-linking agent.
- the concentration of the collagen in the suspension at the time of cross-linking, the concentration of the cross-linking agent, and the duration of the cross-linking reaction are important process conditions for obtaining the kind and degree of cross-linking that provides a product having enhanced persistence.
- the collagen can be cross-linked by any of a number of conventional chemical cross-linking agents, including, but not limited to, glutaraldehyde, divinylsulfone, epoxides, carbodiimides, imidazole, N-hydroxy-succinimide (NHS), thiol derivatized polyethylene glycol (PEG), and the like.
- glutaraldehyde divinylsulfone
- epoxides epoxides
- carbodiimides imidazole
- N-hydroxy-succinimide (NHS) N-hydroxy-succinimide
- PEG thiol derivatized polyethylene glycol
- Aldehydes are preferred cross-linking agents.
- aldehydes that may be used to cross-link collagen are formaldehyde, acetaldehyde, glyoxal pyruvic aldehyde, and dialdehyde starch.
- Glutaraldehyde is particularly preferred.
- Compounds that have functional groups that react with the functional groups of the cross-linking agent (e.g., aldehyde group) to form water soluble adducts may be used to quench the cross-linking reaction. Quenching agents that have free amino groups such as amino acids are preferred. Glycine is particularly preferred.
- the concentration of glutaraldehyde in the reaction mixture is typically about 0.001% to about 0.05% by weight.
- the glutaraldehyde reacts with hydroxy lysine and lysine residues of the collagen fibers, thereby reducing the number of free hydroxy lysine and lysine in the collagen.
- the number of free hydroxy lysine and lysine residues per 1000 amino acid residues after cross-linking is about 22-32, more typically about 24-29.
- Hydroxy lysine and lysine content may be measured by reducing the cross-linked collagen with borohydride and hydrolyzing the reduced material under vacuum in 5.7 N HCl for 24 hours at 1000 C.
- Amino acid analysis may be performed with available analyzers (e.g., a Durrum Model D-500 analyzer) and the hydroxy lysine and lysine residues quantified by comparing the hydroxy lysine and lysine/alanine ratio to those observed in non-cross-linked controls.
- analyzers e.g., a Durrum Model D-500 analyzer
- the hydroxy lysine and lysine residues quantified by comparing the hydroxy lysine and lysine/alanine ratio to those observed in non-cross-linked controls.
- the duration of the cross-linking reaction is usually in the range of one-half hour to about one week.
- the reaction is normally carried out at about 10° C. to about 35° C.
- the quenching agent is added in at least stoichiometric proportions relative to the cross-linking agent.
- a particularly preferred cross-linking protocol is about 38 to about 52 mg/mL collagen concentration, pH about 4.2 to about 5.0, and about 0.01% by weight glutaraldehyde for about 16 hours at approximately 22° C.
- the cross-linked collagen product may be washed with an aqueous buffer solution to remove unreacted aldehyde, aldehyde polymers, and, if quenching was employed, unreacted quenching agent, and aldehyde-quenching agent adducts.
- a sodium phosphate-sodium chloride buffer solution pH 6.9 to 7.4, is preferred.
- the washed product may be concentrated, such as by filtration or centrifugation, to a suitable protein concentration range, typically about 20 to about 65 mg/mL, more usually about 25 to about 40 mg/mL. Protein concentration may be adjusted to this range by addition of buffer or further concentration, as the case may be.
- the washed product has a free aldehyde content below about 20 ppm.
- Formulation of the cross-linked collagen typically involves adjusting the ionic strength to isotonicity (i.e., about 0.15 to about 0.2) and adding a local anesthetic, such as lidocaine, to a concentration of about 0.3% by weight to reduce local pain upon injection.
- a particularly preferred cross-linking product has a collagen concentration of 30.0-37.0 mg/mL, a lidocaine concentration of 2.7-3.3 mg/mL, and a pH of 7.0-7.6.
- the cross-linked product is further homogenized, smoothed by microfluidization, and screened by forcing the collagen fibers through a screen of defined pore size.
- the cross-linked collagen is then loaded into syringes fitted with a #25 gauge or larger gauge needle for injection.
- injectable means that the formulation can be dispensed from syringes having a gauge as low as #25 under normal manual pressure without substantial spiking.
- the above described steps for preparing the inventive cross-linked collagen are preferably carried out in sterile conditions using sterile materials.
- the cross-linked collagen of the present invention may be injected intradermally or subcutaneously to augment soft tissue, to repair or correct congenital anomalies, acquired defects or cosmetic defects.
- congenital anomalies such as hemifacial microsomia, malar and zygomatic hypoplasia, unilateral mammary hypoplasia, pectus excavatum, pectoralis agenesis (Poland's anomaly), and velopharyngeal incompetence secondary to cleft palate repair or submucous cleft palate (as a retropharyngeal implant); acquired defects (post traumatic, post surgical, or post infectious) such as depressed scars, subcutaneous atrophy (e.g., secondary to discoid lupis erythematosis), keratotic lesions, enopthalmos in the unucleated eye (also superior sulcus syndrome), acne pitting of the face, linear scleroderma with subcutaneous atrophy, saddle-nose deformity, Rom
- the invention provides a soft tissue augmentation injectable that fills the space with a durable strong biocompatible bulking agent.
- the collagen fiber of the present invention is reduced in size and forms a network that takes up more space.
- the inventive cross-linked collagen is elastic and resilient. It keeps its shape over time and resists breakdown and cellular infiltration.
- Purified, type I, pepsin digested human collagen from Allergan Medical Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) was precipitated by raising the pH to 7.0-7.6 and then centrifuging at 17000 ⁇ g for 5-7 minutes. The supernatant was aseptically decanted from the centrifuge bottle, and the collagen pellet aseptically suctioned into a homogenization vessel. The precipitated collagen was aseptically homogenized. The protein concentration was 91.6 mg/mL.
- 3000 ppm glutaraldehyde buffer was mixed with the acid homogenate. The mixture was allowed to incubate for 1.5 hours and remixed, further incubated for 23 hours and remixed, and incubated again for 72 hours and remixed.
- the protein concentration was 37.1 mg/mL; the pH was 4.6.
- the cross-linked homogenate was mixed with 0.5 M sodium phosphate buffer, pH 11.2, followed by 0.04 M sodium phosphate/2.6 M sodium chloride/60 mg/mL lidocaine buffer. The homogenate was allowed to incubate for 24 hours and remixed. The protein concentration was 31.9 mg/mL. The formulated homogenate was then passed through a microfluidizer and screened.
- the conventional cross-linked collagen was obtained by precipitating and cross-linking purified, type I, pepsin digested human collagen from Allergan Medical Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) at about 3 mg/mL and a neutral pH.
- the conventional cross-linked collagen was harvested by centrifugation, and then homogenized, formulated, smoothed using microfluidization and screened.
- the inventive cross-linked collagen was obtained by precipitating purified, type I, pepsin digested human collagen from Inamed Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) at about 3 mg/mL at a neutral pH and harvesting the collagen by centrifugation. The pH was reduced to 4.4-4.8, and the collagen was cross-linked. The inventive cross-linked collagen was then homogenized, formulated, smoothed using microfluidization, and screened.
- inventive cross-linked collagen was tested and compared to that of the conventional cross-linked collagen. Safety was assessed through a cytotoxicity study and multiple rabbit subcutaneous implantation studies. The data demonstrates that the inventive cross-linked collagen, like the conventional cross-linked collagen, was biocompatible.
- the inventive cross-linked collagen implants caused no cell lysis or toxicity (Table I).
- the rabbit subcutaneous implantation assay was used to compare tissue responses to the conventional and inventive cross-linked collagen implants at several different time-points.
- the tissue response to the inventive implant was similar to that seen with the conventional implant (Table II).
- the microscopic scores ranging from non-irritant to slight irritant are within the range of acceptable variability and considered to be satisfactory.
- a rat subcutaneous implantation study was performed to compare the persistence of the inventive cross-linked collagen implant relative to the conventional cross-linked collagen implant. As part of the rat implantation study, a macroscopic evaluation of the implant site was performed. There was no capsule formation or adverse reaction for either implant for all time points studied (Table III).
- the data from the rat subcutaneous studies, summarized in FIG. 2 indicates that the inventive implant, on average, had greater wet weight recovery and maintained its height better than the conventional implant after 24 weeks of implantation.
Abstract
The present invention discloses collagen cross-linked in a micro to non-fibrillar form and at a high concentration. The cross-linked collagen gel has improved volume stability or persistence than collagen cross-linked at a neutral pH. Also disclosed are methods for preparing the inventive cross-linked collagen and using such for augmenting soft tissues in mammals.
Description
- This application is based, and claims priority under 35 U.S.C. § 120 to U.S. Provisional Patent Application No. 60/939,664 filed on May 23, 2007 and which is incorporated herein by reference.
- The present invention relates in general to body treating compositions and methods. More specifically, the invention provides a cross-linked collagen implant of improved volume stability (“persistence”) for augmenting soft tissue in mammals.
- Collagen has been used as a pharmaceutical carrier, as a surgical prosthesis (sutures and wound dressings), and as an implant material. In many instances, the collagen is cross-linked with chemical agents, radiation, or other means to improve its mechanical properties, decrease its immunogenicity, and/or increase its resistance to resorption. For example, U.S. Pat. No. 4,424,208 describes a collagen composition including cross-linked collagen and reconstituted collagen fibers having enhanced persistence. While these materials are remarkably effective, they shrink in volume after implantation due primarily to absorption of their fluid component by the body, although the shrinkage (syneresis) is less than non-cross-linked collagen. Since a constant volume or persistence is desirable, an additional injection or injections of supplemental implant material is required. It would thus be advantageous to provide collagen compositions having enhanced persistence after being introduced in vivo to a soft tissue treatment site.
- The present invention relates to collagen cross-linked in a micro to non-fibrillar form and at a high concentration for augmenting soft tissue in mammals. The cross-linked collagen of the present invention has improved volume stability or persistence compared with collagen cross-linked at a neutral pH.
- In one aspect, the invention features a method for preparing cross-linked collagen. The method involves the steps of obtaining micro to non-fibrillar collagen, treating the micro to non-fibrillar collagen with a cross-linking agent, and isolating cross-linked collagen. The micro to non-fibrillar collagen may be obtained by incubating fibrillar collagen in a suspension or solution of pH 2-5 or pH 9-12. In a preferred embodiment, the pH of the suspension or solution is between 4.2 and 5.0. The concentration of the micro to non-fibrillar collagen at the time of cross-linking is in the range of 3-150 mg/mL, and preferably, 38-52 mg/mL. Typically, the treating step includes treating the micro to non-fibrillar collagen with the cross-linking agent at pH 2-5 or pH 9-12, followed by treating the micro to non-fibrillar collagen with the cross-linking agent at pH 6-8 to encourage completion of the cross-linking. The method of the invention optionally may further include a step of admixing a local anesthetic agent (e.g., lidocaine) with the cross-linked collagen. Cross-linked collagen so prepared is within the invention.
- Also provided in the present invention is cross-linked collagen comprising micro to non-fibrillar collagen and a cross-linking agent. The micro to non-fibrillar collagen is cross-linked by the cross-linking agent. Such cross-linked collagen may be prepared according to the method described above.
- The cross-linked collagen may derive from type I, II, III, IV, or V collagen, or a combination thereof. It may also derive from telo-containing collagen, atelo-collagen, or derivatized collagen, or a combination thereof.
- Preferably, the cross-linking agent is capable of forming covalent bonds between amino acid residues in the micro to non-fibrillar collagen. Examples of suitable cross-linking agents include, but are not limited to, carbodiimides, polyaldehydes, polysulfones, activated PEGs, epoxides, imidazoles, and diisocyanates. In one embodiment, the cross-linking agent is glutaraldehyde.
- In some embodiments of the cross-linked type I collagen, the number of free hydroxy lysine and lysine residues per 1000 amino acid residues is in the range of 22-32, and more typically, in the range of 24-29.
- The cross-linked collagen of this invention is in a gel but not fibrous state. It locks water in the gel and does not disperse like a fibrous collagen suspension. The cross-linked collagen in a gel state maintains its shape in vivo better than cross-linked collagen in a fibrous state. The fibers of the cross-linked collagen are smaller than those of fibrous collagen cross-linked at a neutral pH.
- The invention further provides a composition containing the cross-linked collagen of the invention and a local anesthetic agent such as lidocaine. The local anesthetic agent is admixed with the cross-linked collagen. In addition, the invention provides a packaged product containing a syringe fitted with a needle, wherein the syringe is loaded with the cross-linked collagen of the invention.
- In another aspect, the invention features a method for filling voids and defects and increasing tissue volume in a mammal. The method involves administering to a mammal the cross-linked collagen of the invention. Preferably, the cross-linked collagen is administered by intradermal or subcutaneous injection.
- As used herein, “micro to non-fibrillar collagen” refers to collagen with a diameter of 5-70 nm; “fibrillar collagen” refers to collagen with a diameter of >70 nm; “fibrous collagen” refers to fibrillar collagen and larger fibers. “Telo-containing collagen” refers to collagen with intact telo peptide; “atelo-collagen” refers to collagen wherein the telo portions are removed partially or totally; “derivatized collagen” refers to chemically modified collagen. Examples of derivatized collagen include, but are not limited to, deamidated, methylated, succinylated, and phosphorylated collagen. Cross-linked collagen in a “gel state” contains micro to non-fibrillar collagen with a fiber diameter range of 5-70 nm; cross-linked collagen in a “fibrous state” contains fibrillar collagen with a fiber diameter of greater than 70 nm.
- As used herein, “free hydroxyl-lysine and lysine” in collagen refers to unmodified hydroxyl-lysine and lysine; “neutral pH” refers to pH 6-8.
- The present invention provides a cross-linked collagen filler for augmenting and filling soft tissue defects and voids with a material that plumps and bulks the soft tissue. The cross-linking collagen of the invention is particularly useful for deep dermal correction and sculpting. The superior shape retention makes it ideal for areas that are hard to correct and where a biocompatible bolus can provide mechanical strength to the body.
- The above-mentioned and other features of this invention and the manner of obtaining and using them will become more apparent, and will be best understood, by reference to the following description, taken in conjunction with the accompanying drawings. The drawings depict only typical embodiments of the invention and do not therefore limit its scope.
-
FIG. 1 is a flow chart illustrating representative conventional and inventive processes for preparation of cross-linked collagen. -
FIG. 2 shows the persistence of the inventive cross-linked collagen relative to the conventional cross-linked collagen. - The present invention is based, at least in part, on the unexpected discovery that collagen cross-linked in a micro to non-fibrillar state and preferably at a high concentration has improved persistence compared to collagen cross-linked at a neutral pH.
- More specifically, fibrillar collagen is fairly porous and allows the transport of cells and large molecules. By cross-linking smaller fiber (microfibrillar) collagen, more rigidity within the network was created to further increase the diffusion hindrance (Rosenblatt and Shenoy, 1993, Chain Rigidity and Diffusional Release in Biopolymer Gels, Proceed Intern Symp Control Rel Bioact Mater 20, Controlled Release Society, Inc.). While fibrillar collagen matrices are capable of moderating the diffusion of large molecules, smaller fiber and non-fibrillar collagen can modulate the diffusion of smaller molecules (Rosenblatt et al., 1989, The Effect of Collagen Fiber Size Distribution on the Release Rate of Protein from Collagen Matrices by Diffusion, J Controlled Release 9:195-203). Cross-linked micro-fibrillar collagen has a tighter network or mesh, which creates a collagen matrix more resistant or persistent to biological degradation. In the present invention, as described in the Example below, type I collagen matrices were modified to reduce the penetration of cells and proteins into the matrices.
- The present invention is particularly directed to the filling of voids and defects and increasing tissue volume in mammals with injectable cross-linked Type I/III collagen implants. Accordingly, the invention provides a method for preparing cross-linked collagen by cross-linking collagen in a micro to non-fibrillar state and preferably at a high concentration.
- The cross-linked collagen of the present invention primarily derives from mammalian source materials, such as bovine or porcine corium, although human placenta material, collagen produced from human fibroblast cell culture, or recombinantly produced collagen expressed from a cell line may also be used. The donor need not be genetically similar to the host into which the material is ultimately implanted.
- Referring to
FIG. 1 , in a conventional process, purified, type I, pepsin digested human collagen from Allergan Medical Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) is reconstituted from a solution by neutralizing the solution at reduced temperatures and ionic strengths hypotonic relative to physiological conditions. The pH of the solution is raised to a level at which the collagen in solution reaggregates into fibrils. The reconstituted fibrous collagen is cross-linked with a cross-linking agent at a neutral pH. The cross-linked collagen is then harvested by centrifugation, formulated/homogenized, smoothed, and screened. - In contrast, the process of the present invention involves concentrating the collagen suspension by centrifugation. The pellet is homogenized, and the pH is adjusted to a non-neutral level prior to cross-linking. The collagen concentration at the time of cross-linking is usually in the range of 3-150 mg/mL, more typically 30-60 mg/mL, 35-55 mg/mL, or 38-52 mg/mL. The pH is adjusted to a non-neutral level appropriate for the cross-linking agent to be used. For example, the pH may be adjusted to about 4.5 for cross-linking by glutaraldehyde or to about 10 for cross-linking by divinylsulfone. A dilute solution of HCl or the like is typically added to adjust the pH to a desired acidic level, while NaOH or the like is used for adjusting the pH to a desired alkaline level.
- The cross-linking begins at pH 2-5 or pH 9-12, more preferably at pH 2-3, 2-4, 3-4, 3-5, or 4-5, or pH 9-10, 9-11, 10-11, 10-12, or 11-12. At these pH ranges, the collagen fiber is unraveled to a micro to non-fibrillar state. More lysine groups are exposed and available for cross-linking. In addition, a high collagen concentration increases the reaction rate. The collagen is stabilized while being cross-linked into small fiber structures. Preferably, after the initial cross-linking, the pH is further adjusted to a neutral pH, e.g., pH 6-8, using 0.5 M phosphate, pH 11.2, or the like, to encourage complete cross-linking. The pH can then be adjusted back to neutral without causing the cross-linked collagen gel to collapse or to spontaneously form fibers.
- Usually a cross-linking agent is polyfunctional, and more usually bifunctional. The cross-linking conditions of the present invention are such as to produce covalently cross-linked collagen that has improved persistence relative to an implant of a comparable formulation prepared according to the conventional process. When this degree of cross-linking has been reached, the cross-linking reaction is optionally quenched by adding a quenching agent. The quenching agent forms a water soluble adduct with the cross-linking agent. The concentration of the collagen in the suspension at the time of cross-linking, the concentration of the cross-linking agent, and the duration of the cross-linking reaction are important process conditions for obtaining the kind and degree of cross-linking that provides a product having enhanced persistence.
- The collagen can be cross-linked by any of a number of conventional chemical cross-linking agents, including, but not limited to, glutaraldehyde, divinylsulfone, epoxides, carbodiimides, imidazole, N-hydroxy-succinimide (NHS), thiol derivatized polyethylene glycol (PEG), and the like.
- Aldehydes are preferred cross-linking agents. Examples of aldehydes that may be used to cross-link collagen are formaldehyde, acetaldehyde, glyoxal pyruvic aldehyde, and dialdehyde starch. Glutaraldehyde is particularly preferred. Compounds that have functional groups that react with the functional groups of the cross-linking agent (e.g., aldehyde group) to form water soluble adducts may be used to quench the cross-linking reaction. Quenching agents that have free amino groups such as amino acids are preferred. Glycine is particularly preferred. The concentration of glutaraldehyde in the reaction mixture is typically about 0.001% to about 0.05% by weight. The glutaraldehyde reacts with hydroxy lysine and lysine residues of the collagen fibers, thereby reducing the number of free hydroxy lysine and lysine in the collagen. At the glutaraldehyde concentrations mentioned above, the number of free hydroxy lysine and lysine residues per 1000 amino acid residues after cross-linking is about 22-32, more typically about 24-29. Hydroxy lysine and lysine content may be measured by reducing the cross-linked collagen with borohydride and hydrolyzing the reduced material under vacuum in 5.7 N HCl for 24 hours at 1000C. Amino acid analysis may be performed with available analyzers (e.g., a Durrum Model D-500 analyzer) and the hydroxy lysine and lysine residues quantified by comparing the hydroxy lysine and lysine/alanine ratio to those observed in non-cross-linked controls.
- The duration of the cross-linking reaction is usually in the range of one-half hour to about one week. The reaction is normally carried out at about 10° C. to about 35° C. The quenching agent is added in at least stoichiometric proportions relative to the cross-linking agent.
- A particularly preferred cross-linking protocol is about 38 to about 52 mg/mL collagen concentration, pH about 4.2 to about 5.0, and about 0.01% by weight glutaraldehyde for about 16 hours at approximately 22° C.
- After the cross-linking reaction has been terminated, the cross-linked collagen product may be washed with an aqueous buffer solution to remove unreacted aldehyde, aldehyde polymers, and, if quenching was employed, unreacted quenching agent, and aldehyde-quenching agent adducts. A sodium phosphate-sodium chloride buffer solution, pH 6.9 to 7.4, is preferred. The washed product may be concentrated, such as by filtration or centrifugation, to a suitable protein concentration range, typically about 20 to about 65 mg/mL, more usually about 25 to about 40 mg/mL. Protein concentration may be adjusted to this range by addition of buffer or further concentration, as the case may be. The washed product has a free aldehyde content below about 20 ppm.
- Formulation of the cross-linked collagen typically involves adjusting the ionic strength to isotonicity (i.e., about 0.15 to about 0.2) and adding a local anesthetic, such as lidocaine, to a concentration of about 0.3% by weight to reduce local pain upon injection. A particularly preferred cross-linking product has a collagen concentration of 30.0-37.0 mg/mL, a lidocaine concentration of 2.7-3.3 mg/mL, and a pH of 7.0-7.6. The cross-linked product is further homogenized, smoothed by microfluidization, and screened by forcing the collagen fibers through a screen of defined pore size.
- The cross-linked collagen is then loaded into syringes fitted with a #25 gauge or larger gauge needle for injection. In the case of formulations used for dermal augmentation, the term “injectable” means that the formulation can be dispensed from syringes having a gauge as low as #25 under normal manual pressure without substantial spiking.
- The above described steps for preparing the inventive cross-linked collagen are preferably carried out in sterile conditions using sterile materials.
- The cross-linked collagen of the present invention may be injected intradermally or subcutaneously to augment soft tissue, to repair or correct congenital anomalies, acquired defects or cosmetic defects. Examples of such conditions are congenital anomalies such as hemifacial microsomia, malar and zygomatic hypoplasia, unilateral mammary hypoplasia, pectus excavatum, pectoralis agenesis (Poland's anomaly), and velopharyngeal incompetence secondary to cleft palate repair or submucous cleft palate (as a retropharyngeal implant); acquired defects (post traumatic, post surgical, or post infectious) such as depressed scars, subcutaneous atrophy (e.g., secondary to discoid lupis erythematosis), keratotic lesions, enopthalmos in the unucleated eye (also superior sulcus syndrome), acne pitting of the face, linear scleroderma with subcutaneous atrophy, saddle-nose deformity, Romberg's disease, and unilateral vocal cord paralysis; and cosmetic defects such as glabellar frown lines, deep nasolabial creases, circum-oral geographical wrinkles, sunken cheeks, and mammary hypoplasia.
- In particular, the invention provides a soft tissue augmentation injectable that fills the space with a durable strong biocompatible bulking agent. Compared to the conventional cross-linked collagen, the collagen fiber of the present invention is reduced in size and forms a network that takes up more space. The inventive cross-linked collagen is elastic and resilient. It keeps its shape over time and resists breakdown and cellular infiltration.
- The following example is intended to illustrate, but not to limit, the scope of the invention. While such example is typical of those that might be used, other procedures known to those skilled in the art may alternatively be utilized. Indeed, those of ordinary skill in the art can readily envision and produce further embodiments, based on the teachings herein, without undue experimentation.
- Purified, type I, pepsin digested human collagen from Allergan Medical Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) was precipitated by raising the pH to 7.0-7.6 and then centrifuging at 17000×g for 5-7 minutes. The supernatant was aseptically decanted from the centrifuge bottle, and the collagen pellet aseptically suctioned into a homogenization vessel. The precipitated collagen was aseptically homogenized. The protein concentration was 91.6 mg/mL.
- 0.05 M HCl buffer and sterile filtered WFI (water for injection) were mixed with the homogenate. The protein concentration was 44.6 mg/mL; the pH was 4.8.
- 3000 ppm glutaraldehyde buffer was mixed with the acid homogenate. The mixture was allowed to incubate for 1.5 hours and remixed, further incubated for 23 hours and remixed, and incubated again for 72 hours and remixed. The protein concentration was 37.1 mg/mL; the pH was 4.6.
- The cross-linked homogenate was mixed with 0.5 M sodium phosphate buffer, pH 11.2, followed by 0.04 M sodium phosphate/2.6 M sodium chloride/60 mg/mL lidocaine buffer. The homogenate was allowed to incubate for 24 hours and remixed. The protein concentration was 31.9 mg/mL. The formulated homogenate was then passed through a microfluidizer and screened.
- The conventional cross-linked collagen was obtained by precipitating and cross-linking purified, type I, pepsin digested human collagen from Allergan Medical Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) at about 3 mg/mL and a neutral pH. The conventional cross-linked collagen was harvested by centrifugation, and then homogenized, formulated, smoothed using microfluidization and screened. The inventive cross-linked collagen was obtained by precipitating purified, type I, pepsin digested human collagen from Inamed Biomaterials (48490 Milmont Drive, Fremont, Calif. 94538) at about 3 mg/mL at a neutral pH and harvesting the collagen by centrifugation. The pH was reduced to 4.4-4.8, and the collagen was cross-linked. The inventive cross-linked collagen was then homogenized, formulated, smoothed using microfluidization, and screened.
- The biocompatibility of the inventive cross-linked collagen was tested and compared to that of the conventional cross-linked collagen. Safety was assessed through a cytotoxicity study and multiple rabbit subcutaneous implantation studies. The data demonstrates that the inventive cross-linked collagen, like the conventional cross-linked collagen, was biocompatible.
- More specifically, the cytotoxicity study was performed using the ISO Elution Method. The inventive cross-linked collagen implants caused no cell lysis or toxicity (Table I).
-
TABLE I Cytotoxicity Study of the Conventional and Inventive Cross-linked Collagen Implants Percent Cells without Confluent Percent Intrascyto-plasmic Percent Monolayer Rounding Granules Lysis Grade Reactivity Conventional 0 0 0 0 0 None Inventive 0 0 0 0 0 None - The rabbit subcutaneous implantation assay was used to compare tissue responses to the conventional and inventive cross-linked collagen implants at several different time-points. The tissue response to the inventive implant was similar to that seen with the conventional implant (Table II). The microscopic scores ranging from non-irritant to slight irritant are within the range of acceptable variability and considered to be satisfactory.
-
TABLE II Rabbit Implantation Evaluation Time Points Conventional Inventive 1 week Non-irritant Non-irritant 4 weeks Non-irritant Slight irritant 9 weeks Not tested Not tested 12 weeks Non-irritant Slight irritant - A rat subcutaneous implantation study was performed to compare the persistence of the inventive cross-linked collagen implant relative to the conventional cross-linked collagen implant. As part of the rat implantation study, a macroscopic evaluation of the implant site was performed. There was no capsule formation or adverse reaction for either implant for all time points studied (Table III).
-
TABLE III Rat Subcutaneous Macroscopic Evaluation Time Points Conventional Inventive 4 weeks No capsule formation or adverse No capsule formation or reaction adverse reaction 9 weeks No capsule formation or adverse No capsule formation or reaction adverse reaction 13 weeks No capsule formation or adverse No capsule formation or reaction adverse reaction 24 weeks No capsule formation or adverse No capsule formation or reaction adverse reaction - To assess effectiveness, the persistence of the inventive relative to the conventional cross-linked collagen was evaluated using wet weight recovery in conjunction with shape retention in the rat subcutaneous model (McPherson et al., 1988, Development and Biochemical Characterization of Injectable Collagen, J Dermatol Surg Oncol 14, Suppl 1). Shape retention is considered to be good measurement of the collagen implant's ability to maintain wrinkle correction. If the implant cannot maintain its shape, it may not correct a wrinkle effectively.
- The data from the rat subcutaneous studies, summarized in
FIG. 2 , indicates that the inventive implant, on average, had greater wet weight recovery and maintained its height better than the conventional implant after 24 weeks of implantation. - All patents and articles cited herein are incorporated by reference in their entirety.
Claims (42)
1. A method for preparing cross-linked collagen, comprising:
obtaining micro to non-fibrillar collagen;
treating the micro to non-fibrillar collagen with a cross-linking agent; and
isolating cross-linked collagen.
2. The method of claim 1 , wherein the micro to non-fibrillar collagen is obtained by incubating fibrillar collagen in a suspension or solution of pH 2-5 or pH 9-12.
3. The method of claim 2 , wherein the micro to non-fibrillar collagen is obtained by incubating the fibrillar collagen in a suspension or solution of pH 4.2-5.0.
4. The method of claim 1 , wherein the concentration of the micro to non-fibrillar collagen is in the range of 3-150 mg/mL.
5. The method of claim 4 , wherein the concentration of the micro to non-fibrillar collagen is in the range of 38-52 mg/mL.
6. The method of claim 1 , wherein the treating step includes treating the micro to non-fibrillar collagen with the cross-linking agent at pH 2-5 or pH 9-12, followed by treating the micro to non-fibrillar collagen with the cross-linking agent at pH 6-8.
7. The method of claim 1 , wherein the cross-linked collagen derives from type I, II, III, IV or V collagen, or a combination thereof.
8. The method of claim 7 , wherein the cross-linked collagen derives from telo-containing collagen, atelo-collagen or derivatized collagen, or a combination thereof.
9. The method of claim 1 , wherein the cross-linking agent is capable of forming covalent bonds between amino acid residues in the micro to non-fibrillar collagen.
10. The method of claim 9 , wherein the cross-linking agent is selected from the group consisting of carbodiimides, polyaldehydes, polysulfones, activated PEGs, epoxides, imidazoles and diisocyanates.
11. The method of claim 10 , wherein the cross-linking agent is glutaraldehyde.
12. The method of claim 1 , further comprising admixing a local anesthetic agent with the cross-linked collagen.
13. The method of claim 12 , wherein the local anesthetic agent is lidocaine.
14. A method for filling voids and defects and increasing tissue volume in a mammal, comprising administering to a mammal the cross-linked collagen prepared according to the method of claim 1 .
15. The method of claim 14 , wherein the cross-linked collagen is administered by intradermal or subcutaneous injection.
16. Cross-linked collagen prepared according to the method of claim 1 .
17. The cross-linked collagen of claim 16 , wherein the number of free hydroxy lysine and lysine residues per 1000 amino acid residues in the cross-linked collagen is in the range of 22-32.
18. The cross-linked collagen of claim 17 , wherein the number of free hydroxy lysine and lysine residues per 1000 amino acid residues in the cross-linked collagen is in the range of 24-29.
19. The cross-linked collagen of claim 16 , wherein the cross-linked collagen is in a gel but not fibrous state.
20. The cross-linked collagen of claim 19 , wherein the cross-linked collagen locks water in the gel and does not disperse like a fibrous collagen suspension.
21. The cross-linked collagen of claim 19 , wherein the cross-linked collagen in the gel state maintains its shape in vivo better than cross-linked collagen in a fibrous state.
22. The cross-linked collagen of claim 19 , wherein the fibers of the cross-linked collagen are smaller than those of fibrous collagen cross-linked at a neutral pH.
23. A composition comprising the cross-linked collagen of claim 16 and a local anesthetic agent admixed with the cross-linked collagen.
24. The composition of claim 23 , wherein the local anesthetic agent is lidocaine.
25. A packaged product, comprising a syringe and a needle, wherein the syringe is loaded with the cross-linked collagen of claim 16 .
26. Cross-linked collagen, comprising:
micro to non-fibrillar collagen; and
a cross-linking agent,
wherein the micro to non-fibrillar collagen is cross-linked by the cross-linking agent.
27. The cross-linked collagen of claim 26 , wherein the cross-linked collagen derives from type I, II, III, IV or V collagen, or a combination thereof.
28. The cross-linked collagen of claim 27 , wherein the cross-linked collagen derives from telo-containing collagen, atelo-collagen or derivatized collagen, or a combination thereof.
29. The cross-linked collagen of claim 26 , wherein the cross-linking agent is capable of forming covalent bonds between amino acid residues in the micro to non-fibrillar collagen.
30. The cross-linked collagen of claim 29 , wherein the cross-linking agent is selected from the group consisting of carbodiimides, polyaldehydes, polysulfones, activated PEGs, epoxides, imidazoles and diisocyanates.
31. The cross-linked collagen of claim 30 , wherein the cross-linking agent is glutaraldehyde.
32. The cross-linked collagen of claim 26 , wherein the number of free hydroxy lysine and lysine residues per 1000 amino acid residues in the cross-linked collagen is in the range of 22-32.
33. The cross-linked collagen of claim 32 , wherein the number of free hydroxy lysine and lysine residues per 1000 amino acid residues in the cross-linked collagen is in the range of 24-29.
34. The cross-linked collagen of claim 26 , wherein the cross-linked collagen is in a gel but not fibrous state.
35. The cross-linked collagen of claim 34 , wherein the cross-linked collagen locks water in the gel and does not disperse like a fibrous collagen suspension.
36. The cross-linked collagen of claim 34 , wherein the cross-linked collagen in the gel state maintains its shape in vivo better than cross-linked collagen in the fibrous state.
37. The cross-linked collagen of claim 34 , wherein the fibers of the cross-linked collagen are smaller than those of fibrous collagen cross-linked at a neutral pH.
38. A composition comprising the cross-linked collagen of claim 26 and a local anesthetic agent admixed with the cross-linked collagen.
39. The composition of claim 38 , wherein the local anesthetic agent is lidocaine.
40. A packaged product, comprising a syringe and a needle, wherein the syringe is loaded with the cross-linked collagen of claim 26 .
41. A method for filling voids and defects and increasing tissue volume in a mammal, comprising administering to a mammal the cross-linked collagen of claim 26 .
42. The method of claim 41 , wherein the cross-linked collagen is administered by intradermal or subcutaneous injection.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/125,337 US20080293637A1 (en) | 2007-05-23 | 2008-05-22 | Cross-linked collagen and uses thereof |
US12/648,960 US20100099623A1 (en) | 2007-05-23 | 2009-12-29 | Cross-Linked Collagen and Uses Thereof |
US12/649,020 US8338375B2 (en) | 2007-05-23 | 2009-12-29 | Packaged product |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93966407P | 2007-05-23 | 2007-05-23 | |
US12/125,337 US20080293637A1 (en) | 2007-05-23 | 2008-05-22 | Cross-linked collagen and uses thereof |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/649,020 Division US8338375B2 (en) | 2007-05-23 | 2009-12-29 | Packaged product |
US12/648,960 Division US20100099623A1 (en) | 2007-05-23 | 2009-12-29 | Cross-Linked Collagen and Uses Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080293637A1 true US20080293637A1 (en) | 2008-11-27 |
Family
ID=40039895
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/125,337 Abandoned US20080293637A1 (en) | 2007-05-23 | 2008-05-22 | Cross-linked collagen and uses thereof |
US12/649,020 Active US8338375B2 (en) | 2007-05-23 | 2009-12-29 | Packaged product |
US12/648,960 Abandoned US20100099623A1 (en) | 2007-05-23 | 2009-12-29 | Cross-Linked Collagen and Uses Thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/649,020 Active US8338375B2 (en) | 2007-05-23 | 2009-12-29 | Packaged product |
US12/648,960 Abandoned US20100099623A1 (en) | 2007-05-23 | 2009-12-29 | Cross-Linked Collagen and Uses Thereof |
Country Status (7)
Country | Link |
---|---|
US (3) | US20080293637A1 (en) |
EP (1) | EP2152743A2 (en) |
JP (2) | JP2010528046A (en) |
AU (1) | AU2008256819A1 (en) |
BR (1) | BRPI0811784A2 (en) |
CA (1) | CA2687990A1 (en) |
WO (1) | WO2008147867A2 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110077737A1 (en) * | 2007-07-30 | 2011-03-31 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
US8513216B2 (en) | 2007-11-30 | 2013-08-20 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8901078B2 (en) | 2011-07-28 | 2014-12-02 | Harbor Medtech, Inc. | Crosslinked human or animal tissue products and their methods of manufacture and use |
US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
US9387151B2 (en) | 2013-08-20 | 2016-07-12 | Anutra Medical, Inc. | Syringe fill system and method |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
CN105979912A (en) * | 2013-12-03 | 2016-09-28 | 康奈尔大学 | Method of repairing an annulus and collagen gel composition |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2861734B1 (en) | 2003-04-10 | 2006-04-14 | Corneal Ind | CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED |
US20080293637A1 (en) * | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Cross-linked collagen and uses thereof |
US8318695B2 (en) * | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
US8394784B2 (en) * | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US20110171286A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
US20110171311A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
CN104136602B (en) * | 2011-06-23 | 2017-06-09 | 成功大学 | Cell tissue adhesive |
JP7099822B2 (en) | 2014-08-28 | 2022-07-12 | ミメディクス グループ インコーポレイテッド | Collagen-enhanced tissue graft |
WO2016128783A1 (en) | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
WO2017015354A1 (en) * | 2015-07-22 | 2017-01-26 | Anexis, Llc | Collagen based materials and methods of using them |
KR101796914B1 (en) | 2017-07-27 | 2017-11-13 | 주식회사 셀루메드 | Polymer composite for filler comprising collagen and dialdehyde starch |
CN115317668B (en) * | 2022-08-19 | 2023-12-29 | 北京西宏润美医药科技有限公司 | Long-acting microparticle type I collagen implant |
Citations (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US4008327A (en) * | 1975-06-16 | 1977-02-15 | Sandoz, Inc. | Tolyloxypivalophenone derivatives |
US4140537A (en) * | 1975-10-22 | 1979-02-20 | Collagen Corporation | Aqueous collagen composition |
US4273705A (en) * | 1979-10-04 | 1981-06-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for preparing collagen filaments for use in medical treatments |
US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4501306A (en) * | 1982-11-09 | 1985-02-26 | Collagen Corporation | Automatic syringe filling system |
US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US4896787A (en) * | 1987-08-14 | 1990-01-30 | Genus International | Article with resilient hinges becoming rigid under tension |
US4996787A (en) * | 1990-05-29 | 1991-03-05 | Jack N. Holcomb | SigSauer pistol with concealed radio transmitter |
US5009013A (en) * | 1988-11-30 | 1991-04-23 | Wiklund Henry W | Device in machines for the marking of workpieces |
US5087446A (en) * | 1989-02-15 | 1992-02-11 | Chisso Corporation | Skin cosmetics |
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5124333A (en) * | 1989-08-02 | 1992-06-23 | Ube Industries, Ltd. | Aminopyrimidine derivatives and harmful organisms preventive agent |
US5217523A (en) * | 1989-09-23 | 1993-06-08 | Basf Aktiengesellschaft | Pyrazole-3-carboxamides, herbicidal compositions and use |
US5314874A (en) * | 1991-04-19 | 1994-05-24 | Koken Co., Ltd. | Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen |
US5328955A (en) * | 1988-11-21 | 1994-07-12 | Collagen Corporation | Collagen-polymer conjugates |
US5399351A (en) * | 1990-07-09 | 1995-03-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
US5428024A (en) * | 1992-02-28 | 1995-06-27 | Collagen Corporation | High concentration homogenized collagen compositions |
US5531716A (en) * | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5616689A (en) * | 1994-07-13 | 1997-04-01 | Collagen Corporation | Method of controlling structure stability of collagen fibers produced form solutions or dispersions treated with sodium hydroxide for infectious agent deactivation |
US5616611A (en) * | 1989-05-19 | 1997-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α-glycosyl-L-ascorbic acid, and its preparation and uses |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
US5633001A (en) * | 1993-03-19 | 1997-05-27 | Medinvent | Composition and a method for tissue augmentation |
US5880107A (en) * | 1995-12-22 | 1999-03-09 | Chemedica S.A. | Sodium hyaluronate based ophthalmic formulation for use in eye surgery |
US6013679A (en) * | 1989-08-01 | 2000-01-11 | Anika Research, Inc. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6224857B1 (en) * | 1996-10-17 | 2001-05-01 | Fidia, S.P.A. | Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics |
US6335035B1 (en) * | 1995-09-29 | 2002-01-01 | L.A.M. Pharmaceutical Corporation | Sustained release delivery system |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6383218B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Sclero-ceratectomy implant for descemet's membrane |
US6383219B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Implant for deep sclerectomy |
US20030031638A1 (en) * | 2001-07-26 | 2003-02-13 | Joshi Vijay Kumar | Stabilized aqueous acidic antiperspirant compositions and related methods |
US6521223B1 (en) * | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
US6544503B1 (en) * | 1995-06-06 | 2003-04-08 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US20030093157A1 (en) * | 2001-06-29 | 2003-05-15 | Casares Crisoforo Peralta | Biodegradable injectable implants and related methods of manufacture and use |
US20030119985A1 (en) * | 1995-12-18 | 2003-06-26 | Sehl Louis C. | Methods for tissue repair using adhesive materials |
US6685963B1 (en) * | 1998-07-01 | 2004-02-03 | Corneal Industrie | Diphasic injection composition containing dispersed and continuous phases useful for reparative and plastic surgery |
US20040032056A1 (en) * | 2002-08-15 | 2004-02-19 | Koua Vang | Drip retainer |
US6716251B1 (en) * | 1997-06-13 | 2004-04-06 | Aventis Pharmaceuticals Holdings, Inc. | Implant for subcutaneous or intradermal injection |
US6734298B1 (en) * | 1998-11-11 | 2004-05-11 | Farmila-Thea Faraceutici S.P.A. | Cross-linking process of carboxylated polysaccharides |
US20040101959A1 (en) * | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
US20040106616A1 (en) * | 2002-01-17 | 2004-06-03 | Rajagopal Bakthavatchalam | Substituted quinazolin-4-ylamine analogues |
US20050020506A1 (en) * | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
US6852255B2 (en) * | 2001-05-02 | 2005-02-08 | Industrial Technology Research Institute | Method for producing water-insoluble polysaccharides |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US6893466B2 (en) * | 2000-08-30 | 2005-05-17 | Sdgi Holdings, Inc. | Intervertebral disc nucleus implants and methods |
US6903199B2 (en) * | 2000-10-10 | 2005-06-07 | Lg Life Sciences Ltd. | Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof |
US20050136122A1 (en) * | 2003-12-22 | 2005-06-23 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
US20050142152A1 (en) * | 2003-12-30 | 2005-06-30 | Leshchiner Adelya K. | Polymeric materials, their preparation and use |
US20050181007A1 (en) * | 2003-11-20 | 2005-08-18 | Angiotech International Ag | Soft tissue implants and anti-scarring agents |
US20060040894A1 (en) * | 2004-08-13 | 2006-02-23 | Angiotech International Ag | Compositions and methods using hyaluronic acid |
US20060095137A1 (en) * | 2004-10-29 | 2006-05-04 | Seoul National University Industry Foundation | Nanofibrous nonwoven membrane of silk fibroin for guided bone tissue regeneration and manufacturing method thereof |
US20060122147A1 (en) * | 2002-10-04 | 2006-06-08 | David Wohlrab | Combination preparation of hyaluronic acid and at least oe local anesthetic and the use thereof |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
US7166570B2 (en) * | 2003-11-10 | 2007-01-23 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20070026070A1 (en) * | 2003-04-17 | 2007-02-01 | Vonwiller Simone C | Cross-linked polysaccharide composition |
US7192984B2 (en) * | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
US20070066816A1 (en) * | 2002-12-31 | 2007-03-22 | Industrial Technology Research Institute | Method for producing double-crosslinked hyaluronate material |
US7196180B2 (en) * | 1998-09-18 | 2007-03-27 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
US20070078172A1 (en) * | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
US20070077292A1 (en) * | 2005-10-03 | 2007-04-05 | Pinsky Mark A | Compositions and methods for improved skin care |
US20080044476A1 (en) * | 2003-11-12 | 2008-02-21 | Allergan, Inc. | Peripherally administered viscous formulations |
US20080057091A1 (en) * | 2006-07-07 | 2008-03-06 | Novozymes Biopolymer A/S | Compositions with several hyaluronic acid fractions for cosmetic use |
US20080089918A1 (en) * | 2004-11-30 | 2008-04-17 | Comeal Industrie | Viscoelastic Solutions Containing Sodium Hyaluronate And Hydroxypropyl Methyl Cellulose, Preparation And Uses |
US20090018102A1 (en) * | 2005-12-21 | 2009-01-15 | Galderma Research & Development | Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith |
US20090022808A1 (en) * | 2007-05-23 | 2009-01-22 | Allergan, Inc. | Coated Hyaluronic Acid Particles |
US20090028817A1 (en) * | 2007-07-27 | 2009-01-29 | Laura Niklason | Compositions and methods for soft tissue augmentation |
US20090036403A1 (en) * | 2007-07-30 | 2009-02-05 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US20090042834A1 (en) * | 2004-05-07 | 2009-02-12 | S.K. Pharmaceuticals, Inc. | Stabilized Glycosaminoglycan Preparations and Related Methods |
US7491709B2 (en) * | 2005-07-01 | 2009-02-17 | Wayne Carey | Treatment with hyaluronic acid |
US20090093755A1 (en) * | 2007-10-09 | 2009-04-09 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US20090110671A1 (en) * | 2005-08-11 | 2009-04-30 | Satomi Miyata | Agent for enhanching the production of collagen and it's use |
US20090110736A1 (en) * | 2007-10-29 | 2009-04-30 | Ayman Boutros | Alloplastic injectable dermal filler and methods of use thereof |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
US20090143331A1 (en) * | 2007-11-30 | 2009-06-04 | Dimitrios Stroumpoulis | Polysaccharide gel formulation having increased longevity |
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
US20090155362A1 (en) * | 2004-11-24 | 2009-06-18 | Novozymes Biopolymer | Method of cross-linking hyaluronic acid with divinulsulfone |
US20090155314A1 (en) * | 2007-12-12 | 2009-06-18 | Ahmet Tezel | Dermal filler |
US20100028437A1 (en) * | 2008-08-04 | 2010-02-04 | Lebreton Pierre F | Hyaluronic Acid-Based Gels Including Lidocaine |
US20100035838A1 (en) * | 2006-09-19 | 2010-02-11 | Geoffrey Kenneth Heber | Cross-linked polysaccharide gels |
US20100041788A1 (en) * | 2006-02-06 | 2010-02-18 | Bioform Medical, Inc. | Implantation Compositions for Use in Tissue Augmentation |
US20100099623A1 (en) * | 2007-05-23 | 2010-04-22 | Allergan, Inc. | Cross-Linked Collagen and Uses Thereof |
US20100098794A1 (en) * | 2008-10-17 | 2010-04-22 | Armand Gerard | Topical anti-wrinkle and anti-aging moisturizing cream |
US20100098764A1 (en) * | 2007-11-30 | 2010-04-22 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US20100111919A1 (en) * | 2008-10-31 | 2010-05-06 | Tyco Healthcare Group Lp | Delayed gelation compositions and methods of use |
US20100136070A1 (en) * | 2008-12-03 | 2010-06-03 | Jakk Group, Inc. | Methods, devices, and compositions for dermal filling |
US7741476B2 (en) * | 2003-04-10 | 2010-06-22 | Allergan Industrie, Sas | Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and hydrogels thus obtained |
US20110034684A1 (en) * | 2004-11-15 | 2011-02-10 | Shiseido Co., Ltd. | Process For Preparing Crosslinked Hyaluronic Acid Gel |
US7902171B2 (en) * | 2004-01-14 | 2011-03-08 | Reinmueller Johannes | Composition for treating inflammatory diseases |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128827A (en) * | 1938-03-09 | 1938-08-30 | Frank B Killian | Method and apparatus for manufacturing thin rubber articles |
CA807629A (en) | 1966-06-30 | 1969-03-04 | Eigen Edward | Lotion and detergent compositions |
JPS4838158B1 (en) | 1970-10-05 | 1973-11-15 | ||
CA949965A (en) | 1971-12-03 | 1974-06-25 | Robert H. Marchessault | Method of preparing cross-linked starch and starch derivatives |
US4060081A (en) | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4233360A (en) | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
SE442820B (en) | 1984-06-08 | 1986-02-03 | Pharmacia Ab | GEL OF THE CROSS-BOND HYALURONIC ACID FOR USE AS A GLASS BODY SUBSTITUTE |
SE456346B (en) | 1984-07-23 | 1988-09-26 | Pharmacia Ab | GEL TO PREVENT ADHESION BETWEEN BODY TISSUE AND SET FOR ITS PREPARATION |
US4605691A (en) * | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
FR2608456B1 (en) | 1986-12-18 | 1993-06-18 | Mero Rousselot Satia | MICROCAPSULES BASED ON GELATIN AND POLYSACCHARIDES AND PROCESS FOR OBTAINING THEM |
US5385938B1 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of using glycolic acid for treating wrinkles |
IT1219587B (en) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
US5475052A (en) * | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
US5643464A (en) * | 1988-11-21 | 1997-07-01 | Collagen Corporation | Process for preparing a sterile, dry crosslinking agent |
US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
EP0416250A3 (en) | 1989-08-01 | 1991-08-28 | The Research Foundation Of State University Of New York | N-acylurea and o-acylisourea derivatives of hyaluronic acid |
CA2023922A1 (en) | 1989-09-05 | 1991-03-06 | James M. Curtis | Method of manufacturing an implantable article provided with a micropillared surface |
JP2832848B2 (en) | 1989-10-21 | 1998-12-09 | 株式会社林原生物化学研究所 | Crystal 2-O-α-D-glucopyranosyl-L-ascorbic acid, its production method and use |
US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
JP3115625B2 (en) | 1991-03-30 | 2000-12-11 | 帝國製薬株式会社 | Topical patch containing lidocaine |
EP0648239A4 (en) * | 1992-07-02 | 1995-09-27 | Collagen Corp | Biocompatible polymer conjugates. |
US5980930A (en) | 1993-01-20 | 1999-11-09 | Bristol-Myers Squibb Company | Fibres |
AU1014695A (en) * | 1994-02-17 | 1995-08-24 | Collagen Corporation | Collagen-synthetic polymer conjugates having controlled fiber size distributions |
CA2146090C (en) | 1994-05-10 | 1998-11-24 | Mark E. Mitchell | Apparatus and method of mixing materials in a sterile environment |
AU706434B2 (en) | 1994-10-18 | 1999-06-17 | Ethicon Inc. | Injectable liquid copolymers for soft tissue repair and augmentation |
FR2733427B1 (en) | 1995-04-25 | 2001-05-25 | W K Et Associes | INJECTABLE BIPHASIC COMPOSITIONS CONTAINING HYALURONIC ACID, ESPECIALLY USEFUL IN REPAIRING AND AESTHETIC SURGERIES |
US5571503A (en) | 1995-08-01 | 1996-11-05 | Mausner; Jack | Anti-pollution cosmetic composition |
US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
PT876165E (en) * | 1995-12-18 | 2006-10-31 | Angiotech Biomaterials Corp | COMPOSITIONS OF RETICULATED POLYMERS AND PROCESSES FOR THEIR USE |
JPH09249751A (en) * | 1996-03-14 | 1997-09-22 | Collagn Corp | Use of hydrophobic crosslinking agent for preparing crosslinked biological material composition |
US5980948A (en) | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
US5935164A (en) | 1997-02-25 | 1999-08-10 | Pmt Corporaton | Laminated prosthesis and method of manufacture |
WO1998054224A1 (en) * | 1997-05-28 | 1998-12-03 | Tapic International Co., Ltd. | Collagen gel |
US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
DK172900B1 (en) | 1998-12-18 | 1999-09-27 | Per Julius Nielsen | Preparation and kit for use in intraocular surgery |
GB9902652D0 (en) * | 1999-02-05 | 1999-03-31 | Fermentech Med Ltd | Process |
US6767928B1 (en) | 1999-03-19 | 2004-07-27 | The Regents Of The University Of Michigan | Mineralization and biological modification of biomaterial surfaces |
US6682760B2 (en) * | 2000-04-18 | 2004-01-27 | Colbar R&D Ltd. | Cross-linked collagen matrices and methods for their preparation |
KR20010096388A (en) | 2000-04-19 | 2001-11-07 | 진세훈 | Human glans enhancing materials and glans enhancing method |
FR2811996B1 (en) | 2000-07-19 | 2003-08-08 | Corneal Ind | CROSS-LINKING OF POLYSACCHARIDE (S), PREPARATION OF HYDROGEL (S); POLYSACCHARIDE (S) AND HYDROGEL (S) OBTAINED, THEIR USES |
US6773723B1 (en) | 2000-08-30 | 2004-08-10 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
US6924273B2 (en) | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
AU2001294459A1 (en) | 2000-10-06 | 2002-04-15 | Jagotec Ag | A controlled-release, parenterally administrable microparticle preparation |
US6599627B2 (en) | 2000-12-13 | 2003-07-29 | Purdue Research Foundation | Microencapsulation of drugs by solvent exchange |
US6979440B2 (en) | 2001-01-29 | 2005-12-27 | Salvona, Llc | Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric |
US7119062B1 (en) | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
JP4230135B2 (en) | 2001-08-21 | 2009-02-25 | 独立行政法人科学技術振興機構 | Method for producing glycosaminoglycan-collagen complex cross-linked by multifunctional cross-linking agent |
US20040127932A1 (en) | 2002-09-12 | 2004-07-01 | Shah Tilak M. | Dip-molded polymeric medical devices with reverse thickness gradient, and method of making same |
AU2003300022A1 (en) | 2002-12-30 | 2004-07-29 | Angiotech International Ag | Silk-containing stent graft |
WO2004087007A2 (en) | 2003-03-25 | 2004-10-14 | Biocure, Inc. | Hydrogel string medical device |
JP2004323453A (en) | 2003-04-25 | 2004-11-18 | Chisso Corp | Decomposable gel and method for producing the same |
JP4208843B2 (en) | 2003-05-13 | 2009-01-14 | 三益半導体工業株式会社 | Wafer isolation method, wafer isolation apparatus, and wafer isolation transfer machine |
WO2005012364A2 (en) | 2003-07-30 | 2005-02-10 | Anteis S.A. | Complex matrix for biomedical use |
WO2005040224A1 (en) | 2003-10-29 | 2005-05-06 | Teijin Limited | Hyaluronic acid compound, hydrogel thereof and material for treating joint |
AU2005210668A1 (en) | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
US20050226936A1 (en) | 2004-04-08 | 2005-10-13 | Q-Med Ab | Method of soft tissue augmentation |
ES2609105T3 (en) | 2004-05-20 | 2017-04-18 | Mentor Worldwide Llc | Covalent linking method of hyaluronic acid and chitosan |
JP2008502690A (en) | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン, | Phospholipid composition and methods for its preparation and use |
WO2006015490A1 (en) * | 2004-08-13 | 2006-02-16 | Ottawa Health Research Institute | Ophthalmic devices and related methods and compositions |
US7414021B2 (en) | 2004-10-01 | 2008-08-19 | Vincent Carmine Giampapa | Method and composition for restoration of age related tissue loss in the face or selected areas of the body |
US20060222680A1 (en) * | 2005-03-31 | 2006-10-05 | Chunlin Yang | Method of preparing crosslinked collagen microspheres |
WO2006122183A2 (en) | 2005-05-10 | 2006-11-16 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
EP1726299A3 (en) | 2005-05-27 | 2007-04-18 | StratoSphere Pharma AB | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture |
JP5119442B2 (en) * | 2005-07-29 | 2013-01-16 | 国立大学法人 東京医科歯科大学 | Gel and medical material comprising the gel |
JP4982718B2 (en) | 2005-08-31 | 2012-07-25 | 株式会社林原 | Composition for oral intake for beautiful skin |
US20070203095A1 (en) | 2005-12-14 | 2007-08-30 | Anika Therapeutics, Inc. | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
US20070212385A1 (en) | 2006-03-13 | 2007-09-13 | David Nathaniel E | Fluidic Tissue Augmentation Compositions and Methods |
CA2645324A1 (en) | 2006-03-15 | 2007-09-27 | Surmodics, Inc. | Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof |
US20070298005A1 (en) | 2006-06-22 | 2007-12-27 | Marie-Josee Thibault | Injectable composition for treatment of skin defects or deformations |
FR2909560B1 (en) | 2006-12-06 | 2012-12-28 | Fabre Pierre Dermo Cosmetique | HYALURONIC ACID GEL FOR INTRADERMAL INJECTION |
KR100759091B1 (en) | 2006-12-13 | 2007-09-17 | 조강선 | Dermal filler composition |
WO2008098007A1 (en) | 2007-02-05 | 2008-08-14 | Freedom-2, Inc. | Tissue fillers and methods of using the same |
US7776840B2 (en) | 2007-02-21 | 2010-08-17 | Cutanea Life Sciences, Inc. | Methods of use of biomaterial and injectable implant containing biomaterial |
US7939578B2 (en) | 2007-02-23 | 2011-05-10 | 3M Innovative Properties Company | Polymeric fibers and methods of making |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
FR2920000B1 (en) | 2007-08-13 | 2010-01-29 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING HYALURONIC ACID, AND COSMETIC PROCESS FOR DECREASING SIGNS OF AGING |
FR2924615B1 (en) | 2007-12-07 | 2010-01-22 | Vivacy Lab | HYDROGEL COHESIVE BIODEGRADABLE. |
EP2222270B1 (en) * | 2007-12-26 | 2018-11-14 | Mark A. Pinsky | Collagen formulations for improved skin care |
US20090291986A1 (en) | 2008-05-22 | 2009-11-26 | Apostolos Pappas | Composition and method of treating facial skin defect |
US20090297632A1 (en) | 2008-06-02 | 2009-12-03 | Waugh Jacob M | Device, Methods and Compositions to Alter Light Interplay with Skin |
-
2008
- 2008-05-22 US US12/125,337 patent/US20080293637A1/en not_active Abandoned
- 2008-05-22 CA CA002687990A patent/CA2687990A1/en not_active Abandoned
- 2008-05-22 EP EP08756119A patent/EP2152743A2/en not_active Withdrawn
- 2008-05-22 BR BRPI0811784-5A patent/BRPI0811784A2/en not_active IP Right Cessation
- 2008-05-22 JP JP2010509553A patent/JP2010528046A/en active Pending
- 2008-05-22 AU AU2008256819A patent/AU2008256819A1/en not_active Abandoned
- 2008-05-22 WO PCT/US2008/064503 patent/WO2008147867A2/en active Application Filing
-
2009
- 2009-12-29 US US12/649,020 patent/US8338375B2/en active Active
- 2009-12-29 US US12/648,960 patent/US20100099623A1/en not_active Abandoned
-
2014
- 2014-01-24 JP JP2014011077A patent/JP2014128686A/en active Pending
Patent Citations (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US4008327A (en) * | 1975-06-16 | 1977-02-15 | Sandoz, Inc. | Tolyloxypivalophenone derivatives |
US4140537A (en) * | 1975-10-22 | 1979-02-20 | Collagen Corporation | Aqueous collagen composition |
US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
US4273705A (en) * | 1979-10-04 | 1981-06-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for preparing collagen filaments for use in medical treatments |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4501306A (en) * | 1982-11-09 | 1985-02-26 | Collagen Corporation | Automatic syringe filling system |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US5091171B1 (en) * | 1986-12-23 | 1995-09-26 | Ruey J Yu | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US4896787A (en) * | 1987-08-14 | 1990-01-30 | Genus International | Article with resilient hinges becoming rigid under tension |
US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
US5328955A (en) * | 1988-11-21 | 1994-07-12 | Collagen Corporation | Collagen-polymer conjugates |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5009013A (en) * | 1988-11-30 | 1991-04-23 | Wiklund Henry W | Device in machines for the marking of workpieces |
US5087446A (en) * | 1989-02-15 | 1992-02-11 | Chisso Corporation | Skin cosmetics |
US5616611A (en) * | 1989-05-19 | 1997-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α-glycosyl-L-ascorbic acid, and its preparation and uses |
US6013679C1 (en) * | 1989-08-01 | 2001-06-19 | Anika Res Inc | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US6013679A (en) * | 1989-08-01 | 2000-01-11 | Anika Research, Inc. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US5124333A (en) * | 1989-08-02 | 1992-06-23 | Ube Industries, Ltd. | Aminopyrimidine derivatives and harmful organisms preventive agent |
US5886042A (en) * | 1989-08-15 | 1999-03-23 | Tristrata Technology, Inc. | Amphoteric compostion and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5217523A (en) * | 1989-09-23 | 1993-06-08 | Basf Aktiengesellschaft | Pyrazole-3-carboxamides, herbicidal compositions and use |
US4996787A (en) * | 1990-05-29 | 1991-03-05 | Jack N. Holcomb | SigSauer pistol with concealed radio transmitter |
US5399351A (en) * | 1990-07-09 | 1995-03-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5314874A (en) * | 1991-04-19 | 1994-05-24 | Koken Co., Ltd. | Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen |
US5428024A (en) * | 1992-02-28 | 1995-06-27 | Collagen Corporation | High concentration homogenized collagen compositions |
US5633001A (en) * | 1993-03-19 | 1997-05-27 | Medinvent | Composition and a method for tissue augmentation |
US5531716A (en) * | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
US5616689A (en) * | 1994-07-13 | 1997-04-01 | Collagen Corporation | Method of controlling structure stability of collagen fibers produced form solutions or dispersions treated with sodium hydroxide for infectious agent deactivation |
US6544503B1 (en) * | 1995-06-06 | 2003-04-08 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US6335035B1 (en) * | 1995-09-29 | 2002-01-01 | L.A.M. Pharmaceutical Corporation | Sustained release delivery system |
US20030119985A1 (en) * | 1995-12-18 | 2003-06-26 | Sehl Louis C. | Methods for tissue repair using adhesive materials |
US5880107A (en) * | 1995-12-22 | 1999-03-09 | Chemedica S.A. | Sodium hyaluronate based ophthalmic formulation for use in eye surgery |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6224857B1 (en) * | 1996-10-17 | 2001-05-01 | Fidia, S.P.A. | Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics |
US6383218B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Sclero-ceratectomy implant for descemet's membrane |
US6383219B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Implant for deep sclerectomy |
US6716251B1 (en) * | 1997-06-13 | 2004-04-06 | Aventis Pharmaceuticals Holdings, Inc. | Implant for subcutaneous or intradermal injection |
US7192984B2 (en) * | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
US6685963B1 (en) * | 1998-07-01 | 2004-02-03 | Corneal Industrie | Diphasic injection composition containing dispersed and continuous phases useful for reparative and plastic surgery |
US7196180B2 (en) * | 1998-09-18 | 2007-03-27 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
US6734298B1 (en) * | 1998-11-11 | 2004-05-11 | Farmila-Thea Faraceutici S.P.A. | Cross-linking process of carboxylated polysaccharides |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6521223B1 (en) * | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
US6893466B2 (en) * | 2000-08-30 | 2005-05-17 | Sdgi Holdings, Inc. | Intervertebral disc nucleus implants and methods |
US6903199B2 (en) * | 2000-10-10 | 2005-06-07 | Lg Life Sciences Ltd. | Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof |
US6852255B2 (en) * | 2001-05-02 | 2005-02-08 | Industrial Technology Research Institute | Method for producing water-insoluble polysaccharides |
US7314636B2 (en) * | 2001-06-29 | 2008-01-01 | Medgraft Microtech, Inc. | Biodegradable injectable implants containing glycolic acid |
US20030093157A1 (en) * | 2001-06-29 | 2003-05-15 | Casares Crisoforo Peralta | Biodegradable injectable implants and related methods of manufacture and use |
US20030031638A1 (en) * | 2001-07-26 | 2003-02-13 | Joshi Vijay Kumar | Stabilized aqueous acidic antiperspirant compositions and related methods |
US20040106616A1 (en) * | 2002-01-17 | 2004-06-03 | Rajagopal Bakthavatchalam | Substituted quinazolin-4-ylamine analogues |
US20040032056A1 (en) * | 2002-08-15 | 2004-02-19 | Koua Vang | Drip retainer |
US20060122147A1 (en) * | 2002-10-04 | 2006-06-08 | David Wohlrab | Combination preparation of hyaluronic acid and at least oe local anesthetic and the use thereof |
US20040101959A1 (en) * | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
US20070066816A1 (en) * | 2002-12-31 | 2007-03-22 | Industrial Technology Research Institute | Method for producing double-crosslinked hyaluronate material |
US7741476B2 (en) * | 2003-04-10 | 2010-06-22 | Allergan Industrie, Sas | Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and hydrogels thus obtained |
US20070026070A1 (en) * | 2003-04-17 | 2007-02-01 | Vonwiller Simone C | Cross-linked polysaccharide composition |
US20050020506A1 (en) * | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
US7166570B2 (en) * | 2003-11-10 | 2007-01-23 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
US20080044476A1 (en) * | 2003-11-12 | 2008-02-21 | Allergan, Inc. | Peripherally administered viscous formulations |
US20050181007A1 (en) * | 2003-11-20 | 2005-08-18 | Angiotech International Ag | Soft tissue implants and anti-scarring agents |
US8124120B2 (en) * | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
US20050136122A1 (en) * | 2003-12-22 | 2005-06-23 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
US20050142152A1 (en) * | 2003-12-30 | 2005-06-30 | Leshchiner Adelya K. | Polymeric materials, their preparation and use |
US7902171B2 (en) * | 2004-01-14 | 2011-03-08 | Reinmueller Johannes | Composition for treating inflammatory diseases |
US20090042834A1 (en) * | 2004-05-07 | 2009-02-12 | S.K. Pharmaceuticals, Inc. | Stabilized Glycosaminoglycan Preparations and Related Methods |
US20060040894A1 (en) * | 2004-08-13 | 2006-02-23 | Angiotech International Ag | Compositions and methods using hyaluronic acid |
US20060095137A1 (en) * | 2004-10-29 | 2006-05-04 | Seoul National University Industry Foundation | Nanofibrous nonwoven membrane of silk fibroin for guided bone tissue regeneration and manufacturing method thereof |
US20110034684A1 (en) * | 2004-11-15 | 2011-02-10 | Shiseido Co., Ltd. | Process For Preparing Crosslinked Hyaluronic Acid Gel |
US20090155362A1 (en) * | 2004-11-24 | 2009-06-18 | Novozymes Biopolymer | Method of cross-linking hyaluronic acid with divinulsulfone |
US20080089918A1 (en) * | 2004-11-30 | 2008-04-17 | Comeal Industrie | Viscoelastic Solutions Containing Sodium Hyaluronate And Hydroxypropyl Methyl Cellulose, Preparation And Uses |
US20070078172A1 (en) * | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
US7491709B2 (en) * | 2005-07-01 | 2009-02-17 | Wayne Carey | Treatment with hyaluronic acid |
US20090110671A1 (en) * | 2005-08-11 | 2009-04-30 | Satomi Miyata | Agent for enhanching the production of collagen and it's use |
US20070077292A1 (en) * | 2005-10-03 | 2007-04-05 | Pinsky Mark A | Compositions and methods for improved skin care |
US20090018102A1 (en) * | 2005-12-21 | 2009-01-15 | Galderma Research & Development | Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith |
US20100041788A1 (en) * | 2006-02-06 | 2010-02-18 | Bioform Medical, Inc. | Implantation Compositions for Use in Tissue Augmentation |
US20080057091A1 (en) * | 2006-07-07 | 2008-03-06 | Novozymes Biopolymer A/S | Compositions with several hyaluronic acid fractions for cosmetic use |
US20100035838A1 (en) * | 2006-09-19 | 2010-02-11 | Geoffrey Kenneth Heber | Cross-linked polysaccharide gels |
US20090022808A1 (en) * | 2007-05-23 | 2009-01-22 | Allergan, Inc. | Coated Hyaluronic Acid Particles |
US20100099623A1 (en) * | 2007-05-23 | 2010-04-22 | Allergan, Inc. | Cross-Linked Collagen and Uses Thereof |
US20090028817A1 (en) * | 2007-07-27 | 2009-01-29 | Laura Niklason | Compositions and methods for soft tissue augmentation |
US20090036403A1 (en) * | 2007-07-30 | 2009-02-05 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US20090093755A1 (en) * | 2007-10-09 | 2009-04-09 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US20090110736A1 (en) * | 2007-10-29 | 2009-04-30 | Ayman Boutros | Alloplastic injectable dermal filler and methods of use thereof |
US20100004198A1 (en) * | 2007-11-30 | 2010-01-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US20100098764A1 (en) * | 2007-11-30 | 2010-04-22 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US20090143331A1 (en) * | 2007-11-30 | 2009-06-04 | Dimitrios Stroumpoulis | Polysaccharide gel formulation having increased longevity |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
US20090155314A1 (en) * | 2007-12-12 | 2009-06-18 | Ahmet Tezel | Dermal filler |
US20100028437A1 (en) * | 2008-08-04 | 2010-02-04 | Lebreton Pierre F | Hyaluronic Acid-Based Gels Including Lidocaine |
US20100098794A1 (en) * | 2008-10-17 | 2010-04-22 | Armand Gerard | Topical anti-wrinkle and anti-aging moisturizing cream |
US20100111919A1 (en) * | 2008-10-31 | 2010-05-06 | Tyco Healthcare Group Lp | Delayed gelation compositions and methods of use |
US20100136070A1 (en) * | 2008-12-03 | 2010-06-03 | Jakk Group, Inc. | Methods, devices, and compositions for dermal filling |
Non-Patent Citations (1)
Title |
---|
Zeeman et al. (Biomaterials, vol. 20, 1999, pages 921-93) * |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110077737A1 (en) * | 2007-07-30 | 2011-03-31 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US8703118B2 (en) | 2007-10-09 | 2014-04-22 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US8513216B2 (en) | 2007-11-30 | 2013-08-20 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US10391202B2 (en) | 2008-08-04 | 2019-08-27 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10485896B2 (en) | 2008-08-04 | 2019-11-26 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US8822676B2 (en) | 2008-08-04 | 2014-09-02 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10328180B2 (en) | 2008-08-04 | 2019-06-25 | Allergan Industrie, S.A.S. | Hyaluronic acid-based gels including lidocaine |
US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
US11173232B2 (en) | 2008-08-04 | 2021-11-16 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9358322B2 (en) | 2008-08-04 | 2016-06-07 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9238013B2 (en) | 2008-08-04 | 2016-01-19 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9089518B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9089519B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10220113B2 (en) | 2010-01-13 | 2019-03-05 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9855367B2 (en) | 2010-01-13 | 2018-01-02 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9333160B2 (en) | 2010-01-13 | 2016-05-10 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9655991B2 (en) | 2010-01-13 | 2017-05-23 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US10449268B2 (en) | 2010-01-13 | 2019-10-22 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9125840B2 (en) | 2010-03-12 | 2015-09-08 | Allergan Industrie Sas | Methods for improving skin conditions |
US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US9585821B2 (en) | 2010-03-12 | 2017-03-07 | Allergan Industrie Sas | Methods for making compositions for improving skin conditions |
US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9012517B2 (en) | 2010-03-22 | 2015-04-21 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9480775B2 (en) | 2010-03-22 | 2016-11-01 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10111984B2 (en) | 2010-03-22 | 2018-10-30 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9737633B2 (en) | 2011-06-03 | 2017-08-22 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US11000626B2 (en) | 2011-06-03 | 2021-05-11 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
US9950092B2 (en) | 2011-06-03 | 2018-04-24 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9962464B2 (en) | 2011-06-03 | 2018-05-08 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9399084B2 (en) | 2011-07-28 | 2016-07-26 | Harbor Medtech, Inc. | Crosslinked human or animal tissue products and their methods of manufacture and use |
US8901078B2 (en) | 2011-07-28 | 2014-12-02 | Harbor Medtech, Inc. | Crosslinked human or animal tissue products and their methods of manufacture and use |
US9220808B2 (en) | 2011-07-28 | 2015-12-29 | Harbor Medtech, Inc. | Crosslinked human or animal tissue products and their methods of manufacture and use |
US9592320B2 (en) | 2011-07-28 | 2017-03-14 | Harbor Medtech, Inc. | Crosslinked human or animal tissue products and their methods of manufacture and use |
US10611822B2 (en) | 2011-07-28 | 2020-04-07 | Harbor Medtech, Inc. | Crosslinked human or animal tissue products and their methods of manufacture and use |
US11833269B2 (en) | 2011-09-06 | 2023-12-05 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US10434214B2 (en) | 2011-09-06 | 2019-10-08 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9821086B2 (en) | 2011-09-06 | 2017-11-21 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10010483B2 (en) | 2013-08-20 | 2018-07-03 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
US9387151B2 (en) | 2013-08-20 | 2016-07-12 | Anutra Medical, Inc. | Syringe fill system and method |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
US9579257B2 (en) | 2013-08-20 | 2017-02-28 | Anutra Medical, Inc. | Haptic feedback and audible output syringe |
US10010482B2 (en) | 2013-08-20 | 2018-07-03 | Anutra Medical, Inc. | Syringe fill system and method |
CN105979912A (en) * | 2013-12-03 | 2016-09-28 | 康奈尔大学 | Method of repairing an annulus and collagen gel composition |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
Also Published As
Publication number | Publication date |
---|---|
AU2008256819A1 (en) | 2008-12-04 |
BRPI0811784A2 (en) | 2011-05-10 |
US8338375B2 (en) | 2012-12-25 |
CA2687990A1 (en) | 2008-12-04 |
US20100099624A1 (en) | 2010-04-22 |
WO2008147867A3 (en) | 2009-04-30 |
JP2014128686A (en) | 2014-07-10 |
EP2152743A2 (en) | 2010-02-17 |
WO2008147867A2 (en) | 2008-12-04 |
JP2010528046A (en) | 2010-08-19 |
US20100099623A1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8338375B2 (en) | Packaged product | |
US4424208A (en) | Collagen implant material and method for augmenting soft tissue | |
US11833269B2 (en) | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications | |
US4582640A (en) | Injectable cross-linked collagen implant material | |
EP2753647B1 (en) | Hyaluronic acid/collagen- based dermal filler compositions and methods for making same | |
EP2773319B1 (en) | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications | |
AU2008310957B2 (en) | Crossed-linked hyaluronic acid and collagen and uses thereof | |
EP2892575B1 (en) | Hyaluronic acid/collagen- based dermal filler compositions and methods for making same | |
EP0509833A1 (en) | An intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen | |
WO1987004078A1 (en) | Precipitation of collagen in tactoid form | |
EP0089145B1 (en) | Injectable cross-linked collagen implant material | |
KR20230119104A (en) | Silk-hyaluronic acid composition for tissue filling, tissue spacing, and tissue bulking | |
Olmo et al. | Kinetics of in vivo degradation of sepiolite‐collagen complexes: Effect of glutaraldehyde treatment | |
US20190117840A1 (en) | Tissue scaffolds | |
KR101590313B1 (en) | Injectable collagen biomaterials for subcutaneous tissue regeneration | |
JPH0136840B2 (en) | ||
AU591964B2 (en) | Collagen products | |
KR20220033998A (en) | Method for pruduction Atelocollagen with high yield and high purity and Uses thereof | |
DK2773319T3 (en) | HYALURONIC ACID COLLAGEN MATRIX FOR DERMAL FILLING AND VOLUME USING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |